Analysis and Reporting

Analysis and interpretation is often a major hurdle for adoption of next-generation sequencing (NGS) testing in clinical setting

Clinical labs looking to develop NGS testing in-house today face a number of challenges. One of the greatest obstacles often cited is the complexity of analysis and clinical reporting.

Pain points with clinical NGS reporting

Fragmented Data: The information is highly fragmented requiring review of multiple public sources in order to make a proper interpretation.

Time Intensive:  Annotation and interpretation is very time consuming and requires significant due diligence to verify that the assessment is based on the most up-to-date information.

Complex Analysis: Integrating the results of functional studies, the outcomes of clinical trials, medical guideline recommendations and drug labels, and then summarizing this so that it's readily comprehensible to the clinician receiving a clinical report is challenging.

Sample Volume Increase: With growing clinical utility evidence supporting NGS testing, clinical labs are projecting an increase in adoption of NGS tests.

Larger Panels: As sequencing cost continues to decrease and more actionable variants are discovered there will be a trend to move towards using larger panels. 

 

 

 

Making clinical informatics accessible

At Roche Sequencing Solutions, our quest is to make sequencing simple and accessible to clinical labs, empowering clinicians with information needed to deliver personalized healthcare. That’s why Roche Sequencing Solutions is developing a clinical decision support software solution that will help address these challenges and help reduce the time it takes to analyze and report NGS testing results. 

Simplify how clinical labs report on their NGS tests

Roche’s clinical interpretation software aims to simplify how labs report on their NGS tests by offering a curated knowledge base with clinical significance for thousands of the most common variants classified in accordance with AMP guidelines, along with public annotations for millions of additional variants. This will enable pathologists to offer greater value to patients, and their referrers, because the software links the findings to actionable therapy options that are supported by local drug-approval agencies or medical guidelines. The solution reduces curation time and automates the workflow for report generation, which can allow labs to scale to increasing case volumes. 

The NGS clinical interpretation software is part of the Roche Sequencing Solutions portfolio of sequencing products that leverages best-in-class technologies to bring sequencing closer to everyday clinical use.